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https://doi.org/10.1016/j.celrep.2020.107885SUMMARYT cell recognition of peptides presented by human leukocyte antigens (HLAs) is mediated by the highly var-
iable T cell receptor (TCR). Despite this built-in TCR variability, individuals can mount immune responses
against viral epitopes by using identical or highly related TCRs expressed on CD8+ T cells. Characterization
of these TCRs has extended our understanding of the molecular mechanisms that govern the recognition of
peptide-HLA. However, few examples exist for CD4+ T cells. Here, we investigate CD4+ T cell responses to
the internal proteins of the influenza A virus that correlate with protective immunity. We identify five internal
epitopes that are commonly recognized by CD4+ T cells in five HLA-DR1+ subjects and show conservation
across viral strains and zoonotic reservoirs. TCR repertoire analysis demonstrates several shared gene us-
age biases underpinned by complementary biochemical features evident in a structural comparison. These
epitopes are attractive targets for vaccination and other T cell therapies.INTRODUCTION
T cells classically recognize short peptides presented by hu-
man leukocyte antigens (pHLAs) by the membrane-anchored
heterodimeric ab T cell receptor (TCR). Each TCRa and TCRb
chain binds to the pHLA surface primarily using three-amino-
acid loops termed complementarity determining regions
(CDRs). The amino acid sequences of two of these loops,
CDR1 and CDR2, are completely encoded within distinct vari-
able (V) genes (TRAV and TRBV for a and b chains, respec-
tively). The interactions they make with pHLA are termed germ-
line contacts. CDR3 loops are the product of imprecise
recombination between V, diversity (D; in b chain only), and
junctional (J) genes. They are ‘‘hypervariable,’’ with sequences
that bear incomplete resemblance to parent V(D)J genes. It has
been estimated that the theoretical TCR repertoire size is
>1015, with around 25 million unique TCRs thought to be ex-
pressed by an individual (Arstila et al., 1999; Sewell, 2012).
Despite this built-in TCR variability, it has been establishedThis is an open access article undthat individuals can mount immune responses against common
epitopes by using identical or highly related TCRs expressed on
CD8+ T cells (Valkenburg et al., 2016; Venturi et al., 2008).
Moreover, through inspection of TCR sequences selected
against a given epitope, it is possible to cluster sequences
that may bind their target by a similar molecular mechanism
(Dash et al., 2017; Glanville et al., 2017) and, hence, explain
strong biases in V-gene usage or CDR3 amino acid motifs.
This information, in the context of multiple donors with a com-
mon HLA allele, enables the identification of TCR features that
may underpin HLA-linked protective immunity in the popula-
tion. These data aid the exploration of dominant TCR se-
quences that might be targeted by altered peptides (Cole
et al., 2012) or may be more tolerant to point mutations arising
from antigenic shift (Valkenburg et al., 2016). Although these
shared ‘‘rules of engagement’’ have extended our understand-
ing of the molecular mechanisms that govern TCR recognition
of pHLA class I in the CD8+ T cell system, for CD4+ T cells,
such information exists only for HIV infection (Benati et al.,Cell Reports 32, 107885, July 14, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS2016), celiac disease (Broughton et al., 2012; Petersen et al.,
2016), and Mycobacterium tuberculosis infection (Glanville
et al., 2017).
We investigated CD4+ T cell responses to influenza A virus
(IAV) as amodel systemwith obvious relevance to human health.
CD4+ T cell responses to IAV, mediated through recognition of
short peptides presented by HLA class II molecules on the sur-
face of antigen-presenting cells, are essential to multiple anti-
viral processes that confer protection from severe symptomatic
disease during IAV infection (Wilkinson et al., 2012). CD4+ T cell
responses can be directed toward any virion protein; yet,
many studies into T and B cell immunity to IAV have focused
on the external hemagglutinin (HA) and neuraminidase (NA) pro-
teins. Indeed, existing molecular studies on CD4+ T cells and
IAV are limited to the ‘‘universal’’ HA epitope (HA306-318,
PKYVKQNTLKLAT), presented by HLA-DRA1*01:01/HLA-
DRB1*04:01 (Glanville et al., 2017; Hennecke and Wiley, 2002)
and HLA-DRA1*01:01/HLA-DRB1*01:01 (HLA-DR1) (Brawley
and Concannon, 2002; Cameron et al., 2002; Cole et al., 2012;
Hennecke et al., 2000). Although these external proteins are
highly immunogenic, antigenic drift and shift limit their capacity
to provide cross-protective immunity to novel viral strains. In
contrast, the internal IAV proteins are more conserved (Heiny
et al., 2007) and may better mediate cross-protective T cell re-
sponses (Chen et al., 2014; Sridhar et al., 2013; Wilkinson
et al., 2012). Three of these proteins, matrix (M1), nucleoprotein
(NP), and the catalytic subunit polymerase basic-1 (PB-1),
exhibit consistent T cell immunogenicity (Hayward et al., 2015).
Existing knowledge of cross-protective T cell responses to these
proteins is heavily skewed toward CD8+ T cells, specifically to-
ward the M1-derived HLA-A2-presented M158-66-GIL epitope
(Chen et al., 2017; Song et al., 2017; Valkenburg et al., 2016).
To date, there are no structurally defined CD4+ T cell epitopes
from the internal proteins and no TCR repertoire data. Current
knowledge of responses directed at internal IAV proteins has
been derived from immunogenicity assays (DiPiazza et al.,
2016; Wilkinson et al., 2012) or flow cytometry (Ge et al., 2010;
Roti et al., 2008) involving long peptides or whole proteins,
with a minority of work determining the minimal epitope (Chen
et al., 2014).
We focused on the HLA class II molecule HLA-DR1 due to
its high prevalence in the human population and the pre-exist-
ing molecular studies using this HLA type (Cole et al., 2012).
Unbiased epitope mapping of the entire M1, NP, and PB-1
proteins revealed five IAV epitopes that elicited robust and
reproducible responses across multiple HLA-DR1+ subjects.
We conducted a comprehensive analysis of the TCR reper-
toire by using next-generation sequencing (NGS) of HLA-
DR1 multimer-isolated cells against all five epitopes. These
analyses revealed biases in TRAV and, to a lesser extent,
TRBV-gene usage shared across the multiple donors
in vitro. Structural analysis demonstrated specific biochemical
features and complementary electrostatics consistent with the
highly focused gene usage patterns in response to certain epi-
topes. Thus, our findings exemplify how highly immunogenic
CD4+ T cell epitopes are underpinned by TCR recognition
mechanisms shared across multiple HLA-DR1+ individuals,
particularly for TCRa chains.2 Cell Reports 32, 107885, July 14, 2020RESULTS
Identification of Immunodominant Responses to Bona
Fide HLA-DR1 Epitopes from the Internal IAV Proteins
To identify HLA-restricted epitopes within three internal IAV pro-
teins (M1, NP, and PB-1; Table S1), we used an HLA-DR1-
focused epitope mapping strategy in two HLA-DR1+ donors by
using overlapping peptide pools arranged into screeningmatrices
(method described in Figure 1A; results in Figure S1). Fine map-
ping of the T cell responses using shorter 13/14-mer synthetic
peptides based on in silicobinding prediction (Table S2; Andreatta
et al., 2015) was used to isolate five HLA-DR1-restricted
epitopes for further analysis in four HLA-DR1+ donors (Figure 1B):
M117-30-SGP, M1129-142-GLI, M1208-222-QAR, NP302-314-DPF, and
PB-1410-422-GMF. These five peptides elicited themost reproduc-
ible IFN-g+ CD4+ T cell responses across all HLA-DR1+ donors
tested (Figures 1C and S2). An analysis of the literature showed
that two of these epitopes had previously been identified in other
studies:M1129-142-GLI (Chen et al., 2014) andM117-30-SGP (Roth-
bard et al., 1988).
To further quantify and compare recognition of these epitopes,
HLA multimers were used to stain 12- to 14-day peptide-
expanded cultures in five HLA-DR1+ donors (Figures 2A–2C; Fig-
ures S3 and S4). Staining was carried out alongside the universal
epitope HA306-318-PKY (Krieger et al., 1991), which served as a
control for well-characterized and strong recognition. Side-by-
side multimer staining and interferon g (IFN-g) ELISpot were
also performed to confirm the functionality of responding popu-
lations (Figure S3). Robust epitope-specific responses were de-
tected in all donors to the control epitope HA306-318-PKY, with
natural donor-specific variation in response magnitude (range,
6.9%–26.2% CD4+). Of the five internal epitopes tested in five
donors, 24 out of 25 possible responses were positive (defined
as multimer staining/total CD4+ T cells 3 100 > 0.5%; donor-4
DPF was negative). The largest responses, whether measured
in terms of size of CD4+ T cell expansion, or of the median fluo-
rescence intensity (MFI) of multimer positive cells, were consis-
tently to M1129-142-GLI followed closely by HA306-318-PKY (Fig-
ures 2B and 2C).
In order to confirm that these epitopes were truly processed
and presented in the context of viral infection, we infected
DR1+ (class 2 knockout [KO] C57BL/6) mice with X31, lab-
adapted strain of IAV (H3N2) and measured ex vivo IFN-g
ELISpot responses (Figures 2D and 2E). Similar to our
observed patterns in humans, responses to M117-30-SGP
(mean, 22.0 SFC/1M splenocytes; positive response cutoff,
20 spot forming colonies (SFC)/1M; and double background)
and PB-1410-422-GMF (mean, 38.7 SFC) peptides were weak-
est, whereas M1129-142-GLI (mean, 211.3 SFC) and HA306-318-
PKY peptides (mean, 298.7 SFC) had similar frequencies.
However, the dominant responses in the HLA-DR1+ mouse
model were to the NP302-314-DPF peptide, with mean SFC of
583.3. To control for HLA-DR1+ T cell specificity, vaccination
of HLA-DR1 mice (wild type [WT], C57BL/6 background; Fig-
ure 2E) was carried out alongside. The broad immunogenicity
of these epitopes in multiple HLA-DR1+ donors and transgenic
HLA-DR1+ mice identified them as interesting candidates for
further analysis and investigation.
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Figure 1. Identification of HLA-DR1 Epitopes from Three Internal Proteins of IAV
(A) Schematic representation of epitopemapping procedure. HLA-DR1+ donor peripheral bloodmononuclear cells (PBMCs) cultured with influenza peptide pools
were screened on IFN-g ELISpot by using peptide-pulsed HLA-DR1+ antigen-presenting cells (APCs), followed by identification of immunogenic peptides and
use of NetMHCIIpan to elucidate the 9-amino-acid core. Shorter peptides were tested on IFN-g ELISpot, followed by further validation and analysis using HLA-
multimer screens and X-ray crystallographic analysis of peptide-HLA structures.
(B) Table of identified HLA-DR1 epitopes and final peptide sequences used for further analysis. Anchor residues P1, P4, P6, and P9 are listed in far-right column,
as indicated by NetMHCIIpan.
(C) Cumulative IFN-gELISpot responses to identified peptides in four HLA-DR1+ donors. Responses to each peptide per donor (mean of two replicates per donor)
were stacked to give the cumulative response in terms of SFC per 105 cultured cells.
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Figure 2. Quantification of Epitope-Specific CD4+ T Cell Populations in 5 HLA-DR1+ Donors In Vitro and an HLA-DR1+ In VivoMouse Model
(A) Epitope-specific HLA-multimer staining of PBMC lines cultured against HLA-DR1 epitopes. Columns correspond to each donor, and rows correspond to each
epitope indicated on the right-hand side of each row. Populations are gated lymphocytes/live/CD3+. Percentages indicate HLA-multimer+ populations as a
percentage of total lymphocytes/live/CD3+/CD4+ cells (gates were set based on fluorescence minus one [FMO] and irrelevant HLA-DR1 multimer controls).
(B) Boxplots of%CD4+ values all in donors. Values were normalized to corresponding%CD4+ values for the control HA epitope HA306-318-PKY for each donor to
account for culture variation.
(C) Corresponding median fluorescence intensity values of all donors normalized to HA306-318-PKYMFI by donor. Boxplots showmedian and interquartile range;
individual data points are shown as dots for each donor.
(D) Schematic detailing the experimental set up of an in vivo viral challenge model (DR1 X31 [n = 6], DR1 PBS [n = 2], WT X31 [n = 14], and WT PBS [n = 11]).
(E) Ex vivo IFN-g ELISpot response data in response to peptides across four mouse groups. Full axis has been expanded on the left to show values close to the
threshold for a positive response ex vivo (20 SFC) marked by the gray dashed line.
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OPEN ACCESSInternal Epitopes Exhibit Minor Differences in Absolute
Conservation across Zoonotic Reservoirs
Despite the internal IAV proteins exhibiting higher levels of con-
servation relative to HA and NA, sequence variation is still pre-
sent, particularly in the major zoonotic reservoirs of birds and
swine that pose threats to the human population. We analyzed
the sequence conservation of each internal epitope in over
17,000 avian sequences, 27,000 human sequences, and 8,000
swine sequences (Figure 3). The most conserved epitope was
PB-1410-422-GMF, with complete sequence conservation in
41,104 of 41,222 sequences (99.7%) from strains in humans,
birds, and swine (Figures 3A–3F). M117-30-SGP showed the sec-
ond highest conservation, at 97.9% in swine (Figure 3C) and
99.1% in human (Figure 3B), but 85.2% in avian strains (Fig-
ure 3A). Interestingly, both of these epitopes were found to be
least immunogenic in both our mouse and human data (Figure 2).
The more immunogenic epitopes in vitro and in vivo, namely,
M1129-142-GLI, M1208-222-QAR, and NP302-314-DPF, were less
conserved, particularly in swine sequences (Figure 3C). M1129-
142-GLI, the most immunogenic epitope in humans, was
conserved in 61.0% of human sequences (Figure 3B) but consis-
tently contained at least one substitution in avian and swine
strains (Figure 3H), resulting in conservation scores of less than
1% in each reservoir. Although M1208-222-QAR and NP302-314-
DPF both had minimal numbers of identical sequences in human
and swine (Figures 3B, 3C, 3E, and 3F), they were highly
conserved in avian strains, at 86.7% and 98.1% sequence iden-
tity, respectively (Figures 3A and 3D). Due to the pandemic threat
posed by H7N9, H9N2, and H5N1 we indicated these regions
with red boxes on the heatmap in Figure 3D and demonstrated
the conservation of NP302-314-DPF in these highly relevant strains.
Despite the lack of absolute conservation (100% identity) in
the most immunogenic epitopes, when we analyzed the muta-
tional dissimilarity in terms of amino acid substitution (Figures
3G–3K), most mutations were one amino acid away (green
dots). This was particularly striking for the highly immunogenic
M1129-142-GLI (Figure 3H) and NP302-314-DPF (Figure 3J) se-
quences, in which most sequence variation in avian and human
strains, respectively, can be attributed to a single mutation.
Overall, this analysis confirmed that our panel of internal DR1
epitopes were highly conserved and relevant for further study,
not only in humans but also in the major zoonotic reservoirs of
bird and swine.
Epitope-Specific CD4+ T Cell Populations Exhibit
Skewed TRAV and Partial TRBV-GeneUsageBias across
HLA-DR1+ Donors In Vitro
To gain insight into whether CD4+ T cell responses were medi-
ated by highly shared recognition mechanisms, comparable to
those observed for immunodominant HLA class I epitopes
(Chen et al., 2017; Song et al., 2017), we conducted TCR reper-
toire analysis using high-throughput sequencing inmultiple HLA-
DR1+ donors. We isolated multimer+ cells following in vitro pep-
tide expansion (corresponding to plots shown in Figure 2) to
obtain sufficient cell numbers for sequencing (Table S3). Inspec-
tion of the most frequently utilized genes, particularly TRAV and
TRBV genes, may indicate if epitope recognition was dependent
on highly specific germline-encoded contacts and specific bind-ing mechanisms (Adams et al., 2016; Feng et al., 2007; Stewart-
Jones et al., 2003), examples of which are limited in the context
of HLA class II. Indeed, V-gene biases were seen in response to
several epitopes shared across all donors (Figure 4; Data S1).
This was most striking for PB-1410-422-GMF for which more
than 60% of TCRs utilized a single TRAV gene (Figure 4E;
TRAV2, mean gene usage frequency = 62%; number of donors,
n = 3) and predominantly recombined with one of four TRAJ
genes (Figure 4E; chord diagram; TRAJ16, TRAJ17, TRAJ3,
and TRAJ30). This was balanced by a smaller bias toward
TRBV-gene usage (Figure 4K; TRBV20-1, mean = 32%, n = 3)
paired largely with TRBJ2-3. The pattern of TRAV2 bias and its
recombination with multiple TRAJ genes suggested a dominant
TCR-a chain-mediated recognition mechanism that centered on
TRAV-encoded germline residues, at either the CDR1, the
CDR2, or the beginning of the CDR3.
The same trend of dominant TRAV gene bias, coupled with
promiscuous TRAJ recombination, was observed in three other
epitope-specific responses. M1208-222-QAR specific reper-
toires were also directed to a single TRAV gene (Figure 4C;
TRAV38-2/DVB8, mean = 50%, n = 4; mainly coupled with
TRAJ44, TRAJ45, and TRAJ49) and to a much lesser extent a
single TRBV gene (TRBV20-1, 23%, n = 4; Figure 4I). This
was followed by M117-30-SGP that exhibited two TRAV gene
biases (Figure 4A; TRAV13-2, mean = 27%, n = 4; TRAV23/
DV6, mean = 35%, n = 4) but no obvious TRBV gene bias (Fig-
ure 4G). Responses to the control epitope HA306-318-PKY
showed a very similar TRAV and TRBV bias (Figure 4F;
TRAV13-1, mean = 26%, n = 5; TRBV28, mean = 23%; Fig-
ure 4L). For M1129-142-GLI, bias was distributed across three
TRAV genes (TRAV2, mean = 18%; TRAV16, mean = 21%;
and TRAV38-1, mean 11%, n = 5), compounded by weaker
TRBV usage biases and more apparent donor diversity. The
final epitope NP302-314-DPF exhibited the strongest donor dif-
ferences in V-gene bias, with broad usage of many TRAV and
TRBV genes. Inspection of repertoires showed that two donors
responded to NP302-314-DPF with a single TCR sequence for
both TCRa and TCRb, and the remaining two donors had
more diverse profiles (data not shown).
When looking at the overarching patterns in VJ-gene usage
across all epitopes, the narrower usage of TRAV genes
compared with TRBV genes in response to the same epitope
was evident. This was tested through entropy (Figure 4M) and
Kullback Leibler (KL) distance (Figure 4N; measured against
the background repertoire). In response to all epitopes other
than HA306-318-PKY, TRAV usage bias was more focused than
TRBV bias. Overall, our observations of V-gene bias were most
likely to have roots in molecular features that involve germline
contacts. We set out to investigate them through X-ray crystal-
lography, exploring the contacts and biochemical features that
were important for recognition.
Selection of Shared V Genes Is Governed by Germline-
Mediated Peptide Interactions
To find structural mechanisms underpinning our observations of
strong peptide-driven V-gene selection, we solved the structure
of the F11 TCR in complex with HLA-DR1-PKY at a resolution of
1.91 A˚ (Table S5). The F11 TCR (Holland et al., 2018) has beenCell Reports 32, 107885, July 14, 2020 5
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Figure 3. Analysis of HLA-DR1 Epitope Sequence Conservation in Human, Swine, and Avian Zoonotic Reservoirs
Sequence bar charts detailing the number of identical epitope sequences (blue) present in all sequenced IAV strains (black) in birds (A), humans (B), and swine (C).
Corresponding breakdown of these sequences by hemagglutinin (H) and neuraminidase (N) subtypes shown as heatmaps for avian (D), human (E), and swine (F)
sequences; the color scale indicates 100% conserved (blue) to not conserved (black). For each epitope, the details of substitutional divergence from the epitope
sequences listed in Figure 1B are shown in the phylogenetic trees (G–K). Virus sequences with identical epitopes aremarked in red, and the number of amino acid
substitutions are color coded and indicated in the key. Major influenza virus lineages are shown in (G) and apply to the remaining phylogenies in (H–K).
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Figure 4. TCR VJ-Gene Usage Analysis of
In Vitro CD4+ Responses to Conserved Epi-
topes
Percentage frequencies of V and J genes observed in
response to a specific epitope, regardless of clonal
expansion, were calculated for each donor. For each
epitope, these values were summed and normalized
to the number of donors (3–5 depending on epitope)
to give the normalized percentage frequency (bar
charts shown in Data S1).
(A–F) Circos plots showing TRAV- and TRAJ-gene
usage cumulative percentage frequencies are shown.
Chords that link between V and J genes, left and right
of the dashed line, respectively, represent VJ pairing,
with chord thickness proportional to the number of
observed pairs. (A) TRAV usage for SGP, (B) TRAV
usage for GLI, (C) TRAV usage for QAR, (D) TRAV
usage for DFP, (E) TRAV usage for GMF, and (F) TRAV
usage for PKY.
(G–L) Corresponding TRBV and TRBJ usage circos
plots. Genes labeled on the outside of the circos were
enriched above 5%; labels for those below 5%are not
shown. (G) TRBV usage for SGP, (H) TRBV usage for
GLI, (I) TRBV usage for QAR, (J) TRBV usage for DFP,
(K) TRBV usage for GMF, and (L) TRBV usage for PKY.
(M) TRAV and TRBV Shannon entropy values for each
epitope-specific response. Boxplots correspond to
median entropy and interquartile range across all
donors. Dots on top of each boxplot correspond to
specific values for each donor. Higher entropy means
the dataset is more diverse.
(N) TRAV and TRBV KL distance values from the naive
repertoire (see STAR Methods for details on back-
ground V-gene usage). Greater distance values
correspond to less diversity and narrower gene usage
than would be expected from the normal repertoire.
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to the HA1.7 TCR (Cole et al., 2012). Both the F11 TCR and the
HA1.7 TCR (Hennecke et al., 2000) share the use of the TRAV
8-4 gene (enriched in clonotyping; mean, 8%; n = 5), and yet,
each has distinct CDR3 sequences, encoded by different TRAJ
and TRBV genes (Table S6). Thus, we investigated whether the
HA306-318-PKY peptide interactions made by the TRAV8-4-en-
coded region of these two TCRs were conserved (Brawley and
Concannon, 2002). Previous structural studies have described
both situations in epitope recognition, notably the CDR3 editinghypothesis (Deng et al., 2012) and a study
that argued for a reduced role of CDR1
and CDR2 in antigen recognition (Borg
et al., 2005).
The F11 TCR bound to HLA-DR1-PKY
with a canonical binding mode and ex-
hibited similar crossing angle and overall
binding mode to HA1.7 (Table S6). The total
number of sub 4 A˚ contacts made by each
TCR to HLA-DR1-PKY was similar (F11 =
103; HA1.7 = 104), as was the proportion
of contacts contributed by each CDR loop
to binding (Table S6). In each complex,
neither the CDR2a nor CDR2b made anydirect contacts with the peptide. Instead, CDR2b binding ac-
counted for >30% of total TCR contacts and was likely a strong
driver of HLA-DRa specificity (invariant compared with the poly-
morphic HLA-DRb chain). In contrast, CDR1a contacted the
peptide by the germline sequence SSVPPY encoded by
TRAV8-4 in both TCRs, suggesting CDR1a may be a factor in
driving the observed epitope specificity. CDR1a to peptide con-
tacts were mediated by the Vala28 (SSVPPY) in the CDR1a loop
for both complexes, each contacting the peptide at the P2Val
side chain and the P-1Lys (Figures 5A and 5B). In each complex,Cell Reports 32, 107885, July 14, 2020 7
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Figure 5. Structural Germline CDR1 Con-
tacts to the Peptide May Drive V-Gene Us-
age Bias in TCRa and b Chains
CDR1a chain contacts made by F11 (A) and HA1.7
(B); any contacts within 4 A˚ are represented by
dashed black lines. Bond distances of charged
contacts and hydrogens bonds (identified by
proteins, interfaces, structures, and assemblies
[PISA]) are labeled in red text. Amino acid se-
quences of peptide and CDR1 are displayed
below with upward-facing residues (not buried
anchors) in larger font. CDR1b contacts for F11 (C)
and HA1.7 (D) are represented in the same format.
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PKY peptide and the same two peptide residues were in contact
with the germline component of each TCR, regardless of
differing CDR3a sequences, TRAJ genes, and TCRb chains.
Thus, both F11 and HA1.7, which share the enriched TRAV8-4,
exhibit a highly similar overall binding to HLA-DR1-PKY and uti-
lize the germline-encoded CDR1a for HA306-318-PKY epitope
recognition.
At the CDR1b, the less-enriched TRBV24-1 gene in F11
formed one salt bridge to P8Lys (Figure 5C) at 3.8 A˚, in addition
to three van der Waals interactions with the P5Asn. In contrast,
the CDR1b loop of HA1.7 formed a strong triad of charge-based
interactions with the P8Lys of the peptide (Figure 5D; Table S6).
Three salt bridges (involving Glub30 and Aspb28, 2.7–3.1 A˚) and
one hydrogen bond (backbone Aspb28 carbonyl, 2.9 A˚) were
contributed by two CDR1b amino acids surrounding P8Lys,
thus providing a strong peptide-specific interaction that is en-
coded in the germline sequence of the TRBV28 gene. TRBV28
was the most enriched gene in response to HA306-318-PKY
(mean = 23%, n = 5; Figure 4L), demonstrating how favorable
CDR1 to peptide interactions might result in V-gene enrich-8 Cell Reports 32, 107885, July 14, 2020ments, as observed in our NGS data
and previous findings by Hennecke
et al. (2000) based on limited clonal
sequencing data.
Germline TRAV-Encoded CDR3
Residues Do Not Contact the PKY
Peptide
We next explored the CDR3a-to-peptide
interactions and looked for germline-en-
coded residues that might explain the
observed enrichment of the V-genes.
The TRAV8-4 germline CDR3a compo-
nent (CAVS.) did not form peptide con-
tacts in either TCR complex (Figures 6A
and 6B). Intriguingly, both TCRs utilized
the same non-germline-encoded Glua94
to make charge-charge peptide contacts
to the flanking residue (P-1Lys), not the
core of the epitope (Figures 6A and 6B).
Analysis of our clonotyping data showed
acidic residues to be exclusively selected
for at this position (CDR3a residue 5;Figures 6A and 6B, sequence logo plots) across all TRAV8-4-en-
coded CDR3a sequences at the specific lengths used by F11
(4 sequences found in clonotyping data; Figure 6A) or HA1.7
(1 sequence found; Figure 6B). The fact that these residues
were exclusively acidic (Asp or Glu) yet were not germline en-
coded (IMGT sequence database; Lefranc et al., 2015) suggest
a charge-specific enrichment with a structurally defined role in
recognition of the HA306-318-PKY peptide.
The TRBV24 linked CDR3b of F11 positions two charged
acidic residues near the P8Lys (Figure 6C), one germline en-
coded and the other the result of recombination. However, the
germline-encoded (TRBV24, IMGT: CATSDL.) Aspb93 was
limited by orientation within the CDR3 loop, being positioned
away from the P8Lys side chain and not forming any contact
with the peptide. Instead, the non-germline-encoded Glub94
residue formed eight van der Waals contacts (3.2–4.0 A˚) and
positioned its carboxyl (-COO) side chain at 4.0 A˚ from the
P8Lys amino group (-NH3 is colored red in Figure 6C). Overall,
the CDR3b residues of F11 (both germline and hypervariable)
formed more van der Waals contacts but an equivalent number
of polar contacts to the peptide as the CDR1b (12 van der Waals
AB
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Figure 6. CDR3 Analysis Demonstrates that
V-Gene Germline-Encoded CDR3 Residues
Are Not in Contact with the Peptide
Combined structural and CDR-sequence analysis
of CDR3a loop binding to the peptide by F11 (A)
and HA1.7 (B), as well as CDR3b loop binding by
F11 (C) and HA1.7 (D). In each panel, the left col-
umn depicts structural arrangement of each CDR
loop interaction (CDR3a, orange; CDR3b, green)
with the PKY peptide. All contacts within 4 A˚ are
represented as dashed black lines. Residues are
labeled according to side chain functional group
charge (blue = basic, red = acidic, black = neutral).
In each panel, the right column summarizes con-
tacts made by each CDR loop (sequence-linker;
top) and matching motif sequences encoded by
the same V gene and of the same length
(sequence-logo; bottom) within NGS data.
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bridge, respectively; Table S6), potentiating the argument that
germline CDR1 contacts provide a substantial contribution to
peptide specificity.
For the TCRb chain of HA1.7, we observed that CDR1b bind-
ing to HLA-DR1-PKY by the highly enriched TRBV28 gene was
mediated by a triad of charged or polar interactions (structural
contacts in Figure 5D; gene usage in Figure 4L). This interaction
may compensate for the absence of charged residues in CDR3b
encoded by HA1.7. Furthermore, an analysis of all CDR3b se-quences detected from clonotyping that
were 15 residues in length and use
TRBV28 were dominated by uncharged
residues across the central sequence
and a preference for acidic residues at
position 6 and 9 in 2/7 and 3/7 sequences,
respectively (sequence logo plot in Fig-
ure 6D). This finding would support the
hypothesis that TRBV28 CDR1b interac-
tions drive peptide specificity and allow
for weaker interactions to dominate the
CDR3b-peptide interface.
CDR3 Amino Acid Enrichments,
Motifs, and Public Sequences
Reflect Biochemical
Complementarity between TCRs
and the pHLA-II Surface
As part of our structural investigations, we
solved pHLA crystal structures of three
conserved IAV epitopes used for clono-
typic analysis (Figure S5; HLA-DR1-
SGP, HLA-DR1-QAR, and HLA-DR1-
GMF; HLA-DR1-PKY from the F11
complex included for comparison). We
generated peptide omit maps (Fig-
ure S5A), observed density maps (Fig-
ure S5B), and conducted atomic-B-factor
analysis of core and flanking amino acids(Figure S5C) to confirm that observed core 9-mers matched
those predicted by NetMHCIIPan 3.1 (Figure 1B).
Subsequently, inspection of the starkly contrasting electro-
static surfaces of these epitopes (Figure S5D) led us to look for
sequence enrichments in the cognate CDR3 sequences that re-
flected simple biochemical complementarities (for example,
opposite charge or shared hydrophobicity). At the simplest level,
they included measurable enrichments in total CDR3 charge
(Figure 7A) or CDR3 hydrophobicity (Figure 7B), which were
clearly complementary to the surface electrostatics of pHLACell Reports 32, 107885, July 14, 2020 9
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highly basic surface of HLA-DR1-PKY, Figure S5D), as well as
the hydrophobic central surface of HLA-DR1-QAR. We then
extended this analysis to look at CDR3 motifs, independent of
sequence length, using GLAM2 (Figures 7C–7H; Figure S6).
We performed GLAM2 analysis (Bailey et al., 2009) on all
CDR3 sequences specific to each epitope and also split our se-
quences into closely related sub groups by using phylogenetic
analysis (usingMUSCLE; Edgar, 2004) to create neighbor-joining
trees (Figure S6), following methods detailed in Chen et al.
(2017). We found several of the highest scoring motifs (Figures
7C–7F) as well as positional enrichments (Figure 7G-H) obtained
from GLAM2 and phylogenetic analyses of the entire pool of
epitope-specific CDR3 sequences (33–132 sequences) to be
present in the small number of public CDR3 sequences shared
in multiple donors (28 sequences, tabulated in Figure 7 with J
analysis detailed in Table S4). These protein motifs and posi-
tional enrichments were encoded both by germline nucleotides
and by P- and N- nucleotide addition and deletion at the V(D)J
junction. For M1129-142-GLI, the NxGN motif (Figure 7C) origi-
nated from germline sequence of three of the four enriched
TRAJ genes (TRAJ29, TRAJ39, and TRAJ49; Figure 4B) in
response to this epitope. For M1208-222-QAR (Figure 7E), the
LxGxYN motif was partly hypervariable in origin (LxGx) and
partly germline-encoded in the enriched TRBJ1-6 gene (YN,
Figure 4I). The GxPxQ motif evident in CDR3b sequences in
response to NP302-314-DPF was exclusively hypervariable.
Furthermore, this epitope elicited a public CDR3b sequence
(CASSPGGSSYEQYF) in two donors with different TRBV genes,
both interesting features of the response that showed the least V/
J gene bias (Figures 4D and 4J). Although dominant motifs were
not evident in public CDR3a sequences, specifically for M117-30-
SGP (Figure 7G) and HA306-318-PKY (Figure 7H), positional en-
richments of single amino acids of like charge were apparent in
multiple shared sequences. The enrichment of basic residues
was exclusively germline in response to M117-30-SGP at the a
chain (Figure 7G), whereas the enrichment for a central acidic
residue in response to HA306-318-PKYwas present in both the hy-
pervariable region and in germline TRAJ sequences.
Finally, we sought to determine whether the identified public
TCRs were simply representative of highly favorable enrich-
ments arising as a result of V(D)J recombination or were highly
expanded in response to IAV infection from precursors that
were less likely to arise in the natural repertoire. The latter sce-
nario would suggest that public sequences represent important
biochemical binding solutions (among a larger pool of possible
solutions). In contrast, the former would indicate that such se-
quences are merely likely to be found in the naive repertoire and
may not represent crucial biochemical binding solutions (which
may otherwise come from CDR1 and CDR2 contacts or the
partner chain). To do this, we used the optimized likelihood es-
timate of immunoglobulin amino-acid sequences (OLGA) tool
(Sethna et al., 2019) to calculate generation probabilities
(pGen) of each CDR3 (Figure S7). We calculated recombination
probability distributions (Figures S7A and S7B) and then map-
ped onto these distributions the specific pGen values of ‘‘pub-
lic’’ TCR sequences in our dataset (Figures S7C and S7D).
Indeed, several of the public sequences displayed probabilities10 Cell Reports 32, 107885, July 14, 2020that fell toward the higher end of each distribution (particularly
for the CDR3a, for which 75% of public sequences had a pGen
value on or above the median and 35% in the upper quartile).
This analysis indicated that most public CDR3a sequences
we found were the result of highly probable recombination
mechanisms, particularly for the TCRa chain. These observa-
tions were suggestive of highly biased TRAV gene selection
linked to dominant CDR1a contacts with the peptide that may
allow for instances of less stringent CDR3 selection at the
TCRa chain (resulting in public TCRs with high pGen values).
However, for the TCRb chain, the origins of gene selection
and CDR3 importance may be more complex (perhaps due to
D segment insertion).
Ultimately, there exists a spectrum of interaction strength
mediated by the combined effect of CDR1 and CDR3 contacts.
Overall, we have deduced both sets of interactions from our data
and demonstrated how such molecular relationships are the ba-
sis of shared CD4+ T-cell-mediated immunity to conserved IAV
epitopes.
DISCUSSION
TCR recognition of pathogen-derived peptides drives anti-viral
CD4+ T-cell-mediated immunity. For instance, in 2012,Wilkinson
et al. (2012) found CD4+ T cell responses specific to conserved
influenza proteins correlated with heterosubtypic protection
against pandemic IAV (Wilkinson et al., 2012). Yet, our knowl-
edge of which peptides are most commonly recognized across
the population and what facilitates this shared recognition is
limited, especially in the context of HLA class II. This is particu-
larly relevant to IAV, as nearly every adult is expected to have
encountered the virus one or more times in their life, most likely
starting in childhood (Munoz, 2002).
Here, we focused on CD4+ T cell recognition of internal pro-
teins from IAV in the context of HLA-DR1. We identified five
HLA-DR1-restricted epitopes, derived from M1, NP, and PB-1,
that elicited responses in multiple HLA-DR1+ donors. The most
immunogenic of these epitopes, M1129-142-GLI, was able to
stimulate cognate CD4+ T cell populations in culture that were
larger in magnitude and exhibited greater avidity for HLA multi-
mers across all donors than the well-studied HLA class II influ-
enza epitope HA306-318-PKY. An analysis of cognate TCR reper-
toire populations in vitro exhibited biases in TRAV-gene usage
and a comparatively reduced skewing in TRBV-gene usage
and J genes. We searched for interactions that may help explain
such biases by comparing the balance between germline CDR1
and hypervariable CDR3 contacts to HA306-318-PKY in one novel
and one published TCR-pHLA complex structure. This analysis
highlighted CDR1-peptide interactions made by both the TCRa
and TCRb chains that were consistent with dominant gene usage
biases we observed in TCR repertoire data from five HLA-DR1+
donors. This was best exemplified by the observation that the
enriched CDR1b sequence of TRBV28 was paired with a
CDR3b that did not form any salt bridges, in addition to the
consistent position and peptide contacts (P-1 and P2) made
by the TRAV8-4-encoded CDR1a in both structures.
Several studies have already identified the importance of
CDR1-peptide contacts in the recognition of HLA-class II
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Figure 7. CDR3 Amino Acid Enrichments, Motifs, and Public Sequences Found in Sequences Responding to Conserved HLA-DR1 Epitopes
The central six amino acids of CDR3 sequences in response to each epitope were analyzed to quantify overall sequence charge (A) and hydrophobicity (B).
Comparative CDR3 analysis between the output of GLAM2 conducted on either the whole set of CDR3 sequences specific to each epitope or a subgroup of
sequences isolated from phylogenetic analysis detailed in Figure S6, respectively, with corresponding public CDR3 sequences (full details in Table S4). Shown
are those epitopes for which high-scoring motifs (C–F) or positional enrichments (G and H) were observed. Below each motif are the number of sequences given
to the GLAM2 algorithm resulting in the discovery of that motif. For (D) and (G), all CDR3a sequences specific to that epitope were given to the GLAM2 algorithm,
whereas for (C), (E), (F), and (H), CDR3 sequences corresponding to a branch of the phylogenetic tree output fromMUSCLE (Figure S7) were analyzed by GLAM2,
resulting in discovery of the presented motif. In the public sequences, tabulated on the right, amino acids highlighted in bold indicate the motif or enrichment
found in the corresponding output of GLAM2 are indicated on sequence logo plots with an asterisk. Amino acids encoded in either germline V or J genes are
separated by a dash, and amino acids hypervariable in origin are colored red in bold typeset. Detailed V(D)J junctional analysis of all public CDR3 sequences are
given in Table S4.
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OPEN ACCESSepitopes in the context of HIV (Galperin et al., 2018), celiac
disease (Gunnarsen et al., 2017; Petersen et al., 2016), and
HA306-318-PKY (Brawley and Concannon, 2002) using crystallog-
raphy, CDR or peptide mutagenesis, and kinetic analysis and/or
CDR1a sequence randomization. Our work provides further ev-
idence of this in the context of HLA class II and opens up new av-
enues of molecular investigation into CDR1 contacts made with
both the peptide core (P1-P9) and flanking residues (P-1.P-n,
P10.P+n). Future experiments involving mutagenesis of
CDR1 residues and kinetic and crystallographic analyses will
conclusively confirm which CDR1 residues are essential for
epitope recognition and help quantify their effect on binding.
There is still debate as to whether CDR1 and CDR2 contacts
play a dominant role in peptide recognition (Borg et al., 2005;
Deng et al., 2012). This undoubtably points to the fact that the
TCR-pHLA interface is a dynamic interconnected network of in-
teractions both with the peptide, HLA, and between the CDR
loops themselves. As such, ascribing importance to the lesser
studied CDR1 loops and quantifying their exact impact in the
absence of knockon effects is complex but necessary to further
our understanding, particularly in the context of HLA class II.
Furthermore, single-cell cloning and expression of TCRs bearing
dominant TRAV and TRBV genes in response to the epitopes
characterized in this study will generate model systems to facil-
itate molecular investigations into the features of pHLA class II
recognition.
Interestingly, the TCR gene biases we observed in our CD4+
T cell responses to immunodominant epitopes may represent
different mechanisms to those observed for CD8+ T cell re-
sponses to immunodominant viral epitopes, including IAV
(HLA-A*02:01-GILGFVFTL) (Chen et al., 2017; Song et al.,
2017; Valkenburg et al., 2016) and EBV (HLA-A*02:01-
GLCTLVAML) (Annels et al., 2000; Lim et al., 2000; Price
et al., 2005), which are dominated by public TCR bias (memory
T cells bearing near identical TCR sequences). These differ-
ences, which may demonstrate decreased reliance on publicity
at the CDR3, could be related to the divergent nature of peptide
presentation by HLA class I and HLA class II. For instance, the
HLA class I binding groove is closed at each end, and pre-
sented peptides are generally forced to ‘‘kink’’ away from the
HLA groove, forming a central bulge. This feature might act
as a barrier for TCRs to make common HLA contacts and could
limit the breadth of TCRs compatible with a unique peptide
conformation. In contrast, the HLA class II binding groove is
open at both ends and peptides are ‘‘pegged down’’ in four
pockets along the bound nonamer (usually positions 1, 4, 6,
and 9), leading to linear, ‘‘flatter’’ bound peptides. This flatter
surface might enable a greater array of TCR binding modes
and allow a larger degree of TCR-HLA interactions, which
would be expected to reduce exclusivity in terms of TCRs
with compatible antigen-binding sites for a given peptide.
There is evidence suggesting that within the HLA class I sys-
tem, the degree of TCR diversity can be altered depending on
whether the peptide is relatively featureless or structurally
unique (Cukalac et al., 2015). CD8+ T cell responses are usually
cytotoxic in nature, so the decision to activate may require a
greater degree of accuracy to limit self-toxicity. In contrast,
CD4+ T cell responses usually provide help during an immune12 Cell Reports 32, 107885, July 14, 2020response, so there could be an advantage in activating a
greater percentage of the CD4+ T cell population, with less
risk of self-reactivity leading to the direct destruction of healthy
tissue. In summary, our findings exemplify how immunogenic
CD4+ T cell epitopes are underpinned by TCR recognition
mechanisms shared across multiple HLA-DR1+ individuals, ex-
tending our understanding of the mechanisms that control TCR
selection against peptide-HLA class II.
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Materials Availability
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Data and Code Availability
All code used for TCR sequence analysis and generation of figures from crystallographic and repertoire data is available from: https://
github.com/ALGW71/ConservedEpitopesIAV. TCR sequencing data is available from: https://vdjdb.cdr3.net/. All crystal datasets
have been deposited in the Protein Database: https://www.rcsb.org/ under accession numbers: 6R0E, 6QZC, 6QZD, 6QZA. Raw
FCS files are available through the lead contact.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Primary Cell Culture
Fresh blood was obtained from five local HLA-DR1+ donors (age range: 20 – 60, gender: three females and two males). Donors gave
written consent (approved by Medical School Research Ethics Committee, Cardiff University). All material was handled, stored and
documented in line with human tissue act regulations. PBMCswere isolated from fresh blood over ficoll gradient (Lymphoprep, Axis-
Shield). Cultures were set up on day-0. Cells were resuspended at 2 M/mL in ‘‘A5’’ medium [RPMI-1640 (GIBCO) supplemented with
5% human AB serum (heat inactivated, Welsh Blood Transfusion Services), 2 mM l-glutamine, 100 U/mL penicillin, 100 mg/mL strep-
tomycin (all Life Technologies)] and 100 mL (200,000 PBMC) cultured at in U-bottom 96well plate (37C, 5%CO2, sterile water placed
in the outer wells) with peptide or peptide pool at 10 mg/mL (1 mg / 100 mL). Cell-kine (Helvetica Healthcare) was added at 10 mL per
well at day-3. Media supplemented with 40 IU/mL IL-2 (Proleukin, University Hospital of Wales pharmacy) was added at day-6
(100 mL) and replaced at day-9 (100 mL remove, then addedwith care not to disturb the cell pellet). Cells were used for immunoassays
from day-12 up to day-21 (ELISpot only). Prior to assay, cells cultured under the same condition (peptide or peptide pool) were com-
bined, washed 3 times in PBS before resuspension and distribution in A5 medium. For IAV peptide screens 600,000 PBMC were
cultured per condition (three wells, 200,000 per well). For HLA-multimer staining 1 million PBMC were cultured per condition (five
wells, 200,000 cells per well). Staining was carried out between day-12 to day-14.
Cell Lines
174.DR1 APCs from the laboratory of David Cole (Theaker et al., 2016) were cultured (37C, 5% CO2) in RPMI-1640 (GIBCO) sup-
plemented with 10% fetal calf serum (heat inactivated, GIBCO), 2 mM l-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin (all
Life Technologies). Cells were contained in standard culture flasks and passaged (removal of between half and two thirds of the re-
suspended volume) every two to three days. HLA-DR expression was checked by flow cytometry with using an anti-DR antibody
(clone: L243, BioLegend).e3 Cell Reports 32, 107885, July 14, 2020
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FoxP3-DTR mice (Strain: B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J, labeled in Figure 2 as wild-type, WT) and HLA-DR1+ mice [strain:
Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma, a gift from Professor Danny Altmann, Imperial College London] were housed in scan-
tainers on a 12 hour light/dark cycle, ventilated with HEPA filtered air and allowed access to standard mouse chow and water ad
libitum. Each strain of mice was maintained as a homozygous colony. All mice were drug and test naive at the start of the study
and all mice appeared healthy with no signs of disease. Mice had not undergone any previous procedures. Each strain was back-
crossed to a C57/BL6 background for over 10 generations. Mice were kept in specific pathogen-free conditions in accordance
with the United Kingdom’s HomeOffice guidelines. All work was approved by the Animal Welfare and Ethical Review Board (AWERB)
at Cardiff University. Studies followed the ARRIVE guidelines. Micewere allocated to experimental groups by age and sex-match. For
infections, mice were anesthetised using isoflurane and infected intranasally. At 7 – 10 weeks of age, mice were infected intra-nasally
with 1500 pfu of A/Hong Kong/X31 or 50ul of PBS as a control under light anesthesia. Body weight was recorded daily until the mice
were sacrificed at day 14 post infection and spleens isolated for analysis by IFN-g ELISpot (Mabtech). In vivo challenge data was
collected over three repeats of the same experiment. Details of mice weight, ages and gender are given for each experiment. Exp
1: 4 DTR mice (X31), 2 DTR mice (PBS), 2 DR1 mice (X31). All female, 10 weeks old. Starting body weights 20 - 24.6 g. Co-housed
between 2 and 4mice per cage. Exp 2: 3 DR1mice (X31), 4 DTRmice (X31), 4 DTRmice (PBS). All female, 10weeks old. Starting body
weights 20.5 – 24.6 g. Co-housed between 2 and 4mice per cage. Exp 3: 2 DR1 (X31), 2 DR1 (PBS), 6 DTR (X31), 5 DTR (PBS). 3 male
DR1mice, 1 female DR1 mouse, 6 female DTRmice, 5 male DTRmice. 4 DR1 mice aged 9 weeks, 6 DTRmice aged 9 weeks, 5 DTR
mice aged 7 weeks. Starting body weights 16.2 – 28 g. Co-housed n = 3 mice per cage.
METHOD DETAILS
Peptide libraries and pools
Peptide libraries were obtained fromGL Biochem (Shanghai) Ltd as 20-mers in the crude form (50%purity). Peptide sequences over-
lapped by 10 amino acids (Figures S1–S3). Original sources of the sequences are as follows: Matrix Influenza A virus (A/Wilson-
Smith/1933(H1N1) 252 amino acids), 24 overlapping peptides. Nucleoprotein Influenza A virus (A/Ck/HK/96.1/02 (H5N1) 401 amino
acids), 39 overlapping peptides. PB1 Influenza A virus (A/Puerto Rico/8/1934(H1N1) 757 amino acids), 74 overlapping peptides. See
Table S1.
Sequence numbering of influenza proteins
For the internal proteins, sequence numbering was assigned from the startingmethionine referred to a reside-1 and so on. For HA the
structural numbering system was used for the universal epitope HA306-318-PKY, consistent with previous publications.
IFN-g ELISpot
174.DR1 APCs were pulsed in a 96 well plate at a concentration of 200,000 cells per 100 mL with peptide or peptide pool at 10 mg/mL
(1 mg / 100 mL) for 2 hours (37C, 5% CO2) in RPMI 1640 medium (plus L-glutamine and antibiotics). Following pulsing, cells were
washed in PBS (150 mL) three times to remove unbound peptides before resuspension in assay medium. APCs that were not pulsed
with peptide (negative control for ELISpot) were incubated and washed alongside pulsed cells. 75,000 PBMC were cultured on anti-
IFN-g coated ELISPOT plate (MSIPS4510) coated with anti-IFN-g capture antibody (1-D1K, Mabtech) with relevant 50,000 peptide
pulsed APC in a total volume of 150 mL for 16 hours (37C, 5% CO2). Plates were developed following manufacturer’s protocol
(Detect: 7-B6-1-Biotin, Streptavidin-ALP). Positive controls were phytohaemagglutinin-L (PHA, Sigma) and PKY-HA306-318 (Krieger
et al., 1991). Tests were run in duplicate wells, with a single negative control (PBMC and 174.DR1 APCs in the absence of peptide or
PHA stimulation). Developed plates were imaged and counted using a CTL Immunospot analyzer. CTL Single Color software was
used for spot counting and QC. Settings were kept constant for each reading. Assays were normalized for cumulative analysis
(bar graphs displayed in Figures S1–S3) by division of individual well spots by total number of spots across all wells (minus
background).
Binding algorithm prediction
NetMHCIIpan (version 3.1; http://www.cbs.dtu.dk/services/NetMHCIIpan/) was used to predict the epitope based on the strongest
binding core. Sequences 20-30 amino acids in length were input in FASTA format and HLA-DRB1*0101 was the allele selected,
threshold of strong and weak binders was left at default parameters, with ‘print only strongest binding core’ and ‘sort output by af-
finity’ checked. Output lengths of 13-17 amino acids were ranked according to predicted binding affinity and used to design shorter
peptides of 13-14 amino acids in length (one peptide, QAR, was designed at 17 amino acids, 5 residues at the N-terminal flank, 2
residues at the C-terminal, in order to explore order in the N-terminal flank through X-ray crystallography, the same peptide was
used in all cell assays). Shorter peptides were ordered at greater 80% purity (Peptide Protein Research Ltd.).
Production of soluble HLA-DR1 multimers
Soluble peptide-HLA-DR1 was refolded using recombinantly expressed DR1a and DR1b chains with peptide, as described in pre-
vious publications (Cole et al., 2012). Briefly, relevant HLA-DR chains, DR1a: HLA-DRA*01 (Uniprot: P01903, residues [26-207]) orCell Reports 32, 107885, July 14, 2020 e4
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DRB1*0101 (Uniprot: P01911, residues [30-219]) were cloned into the pGMT7 expression vector and expressed in Rosetta (DE3)
competent BL21 E. coli cells (Novagen). Proteins were isolated from inclusion bodies solubilised in 8M urea buffer (20 mM Tris,
pH 8.1, 0.5 mM EDTA, pH 8.1) and purified on AKTA Pure FPLC (GE Healthcare Life Sciences) using a HiTrap Q HP anion exchange
column (GE Healthcare Life Sciences) over a 1M NaCl gradient. Purified DR1a and DR1b chains (5 mg/L) were refolded with peptide
(0.5 mg/L) refolded in a 25% glycerol buffer solution (20 mM Tris, 1 mM EDTA, 20 mM NaCl, 1.48 g/L cysteamine hydrochloride and
0.83 g/L cystamine hydrochloride, stirred for 1 hr, followed by incubation 72 – 120 hr, 4C). Soluble refolded monomer was concen-
trated, and buffer exchanged into PBS using by filtration (10 kDa MWCO concentration cassette, Sartorius AG) followed by concen-
tration in centrifugal filter units (Merck Millipore). Conformationally intact monomer was isolated by immunoaffinity column chroma-
tography (PBS buffer, L243 a-HLA-DR antibody immobilised on Pierce Protein A IgG Plus Orientation kit, ThermoFisher Scientific). If
intended for use in HLA-multimer staining, monomers were biotinylated using a BirA biotinlyation kit (Avidity) in 10 mM TRIS, 10 mM
NaCL buffer pH 7.4. Efficiency of biotinlyation was checked with a biotin shift assay, using monomer incubated with equimolar
amounts of free streptavidin (20 min, RT) before analysis on SDS-PAGE (4%–12% Bis-Tris, BoltTM Invitrogen) using loading buffer
(BoltTM LDS, Invitrogen) in the absence of a reducing agent. Biotinylated monomer was purified by size exclusion column chroma-
tography (Superdex 200 increase 10/300 GL, GE Healthcare Life Sciences) into PBS for HLA-multimers or 10 mM TRIS, 10 mMNaCl
buffer pH 7.4 for use in crystallography.
Preparation of HLA-Multimers
All pHLA monomers used in human experiments were multimerised on a dextramer backbone (‘Klickmer’, Immudex) following pub-
lished methodology (Dolton et al., 2015; Tungatt et al., 2015). Per individual stain, 0.5 mg of refolded and biotinylated pHLAmonomer
was incubated with 2 mL of phycoerythrin (PE)-conjugated dextramer backbone solution (30 min, room temperature) and diluted with
PBS to give 0.1 mg/mL of monomer, with addition of a protease inhibitor cocktail (1:100, set 1, Merck). The volume of dextramer back-
bone added per mg of pHLA monomer is batch dependent and the manufacturer’s guidance should be followed. The pHLA dex-
tramers were centrifuged (> 10000 rpm, 30 s) to pellet aggregated material immediately before use. Multimers could be made on
the day of staining, or up to five days before, stored at 4C.
Human HLA-Multimer Staining
Five PBMC lines of 200,000 cells, cultured as described above, were combined (estimated as 1 million total cells) then split into three
flow cytometry tubes (for test, irrelevant HLA class-II multimer and fluorescence minus one (FMO) control) and washed (800 g, 3 min)
in 3 mL of FACS buffer (PBS supplemented with 10% heat inactivated FCS). Prior to HLA-multimer staining the cells were incubated
with the protein kinase inhibitor Dasatanib (50 nM, 30 min, 37C; Axon Medchem) to maximize productive staining with HLA-multi-
mer. Dasatinibwas stored at80Cas one-use aliquots at 10mM inDMSO. HLA-multimers (0.5 mgwith respect to pHLA component)
were added in a volume of 5 mL directly to PBMC lines in Dasatanib, without washing, and incubated for 30 min at 4C. Lines were
washed as above in FACS buffer and incubated with anti-PE ‘boost’ antibody (0.5 mg per stain, 10 mg/mL, 20 min, 4C; clone PE001,
BioLegend) (Tungatt et al., 2015). The ‘boost’ antibody stabilizes the pHLAmultimer at the cell surface leading to enhanced staining of
the cells. Cells were washed twice in PBS, then stained with violet LIVE/DEAD Fixable Dead Cell Stain, Vivid (Life Technologies) (1:40
pre-dilution in PBS, 2 mL per stain, 5 min, RT). The antibody cocktail of remaining stains was added for incubation (20 min, 4C): anti–
CD8-allophycocyanin-vio770 (1:50, clone BW135/80; Miltenyi Biotec), anti-CD4 allophycocyanin (1:50, clone M-T466; Miltenyi Bio-
tec), anti-CD3-peridinin chlorophyll protein (PerCP) (1:50, clone BW264/56; Miltenyi Biotec); anti-CD19-Pacific blue (1:25, clone
HIB19; BioLegend); and anti-CD14-Pacific blue (1:25, clone M5E2; Bio- Legend). Following antibody cocktail incubation, cells
were washed twice in FACS buffer before analysis by flow cytometry. Cells were sorted on a BD FACS ARIA (BD Biosciences)
with the help of central biology services (CBS) at Cardiff University. Cells were sorted directly into RLT lysis buffer (QIAGEN) supple-
mented with 0.5 M DTT, and frozen at80C for RNA extraction (RNAeasy Plus Micro Kit, QIAGEN) and cDNA isolation (SMARTer
RACE 50/30 Kit, Takara Bio).
Conservation Analysis
To assess conservation of the five HLA-DR1 restricted epitopes (SGP-M117-30; GLI-M1129-142; QAR-M1208-222; DPF-NP273-285; GMF-
PB1410-422) among animal and human influenza viruses, we estimated the exact peptide match among globally circulating human,
swine and avian influenza A viruses using unique amino acid sequences of MP (n = 49,755), NP (n = 51,921) and PB1 (n = 41,222)
proteins of all influenza A subtypes available in NCBI GenBank. To visualize amino acid changes in the five immunogenic epitopes
we reconstructed the phylogenetic relationships of full-length MP, NP and PB1 genes of influenza A viruses using the general time
reversible nucleotide substitution model with gamma rate heterogeneity (GTR+G) using RAxML v8 (Stamatakis, 2014) and visualized
using Figtree (http://tree.bio.ed.ac.uk/software/figtree/).
TCR sequencing
TCR sequencing was performed as previously described (Rius et al., 2018). RNA was extracted from each sample using an RNeasy
Plus Micro Kit (QIAGEN) and used to make cDNA (50/30 SMARTer RACE kit, Takara Bio). The SMARTer approach, utilizing a Murine
Moloney Leukaemia Virus (MMLV) reverse transcriptase, a 30 oligo-dT primer and a 50 oligonucleotide, generated cDNA templatese5 Cell Reports 32, 107885, July 14, 2020
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or the TCR-b constant region (CaR1 50 CCATAGACCTCATGTCTAGCACAG-30 or CbR1 50-GAGACCCTCAGGCGGCTGCTC-30,
EurofinsGenomics, Germany) was then usedwith an anchor-specific forward primer (Takara Bio, France) in for the first PCR reaction:
2.5 mL template cDNA, 0.25 mL High Fidelity Phusion Taq polymerase, 10 mL 5X Phusion buffer, 0.5 mL DMSO (all from Thermo Fisher
Scientific, UK), 1 mL dNTP (50 mM each, Life Technologies, UK), 1 mL of each primer (10 mM), and nuclease-free water to make up a
total reaction volume of 50 mL. Subsequently, 2.5 mL of the first PCR products were used to set up a second PCR (reagent cocktail as
above), using a nested set of primers flanked with Illumina index sequences (CaR2 50-GGTGAATAGGCAGACAGACTTGTC-30 or
CbR2 50-TGTGTGGCCAGGCACACCAGTGTG-30, immediately followed by the Illumina index sequence, Eurofins Genomics, Ger-
many). For both PCR reactions, cycling conditions were: 5 min at 94C, 30 cycles of 30 s at 94C, 30 s at 63C, 90 s at 72C, and
a final 10 min extension at 72C. Final PCR products were loaded on a 1% agarose gel and purified using the QIAEX II gel extraction
kit (QIAGEN, Germany). Purified products were pooled and libraries were processed with the NEBNext Ultra Library preparation kit
(New England Biolabs) and run on an Illumina MiSeq instrument using a MiSeq v2 reagent kit (Illumina). TCR gene usage was deter-
mined based on reference sequences from the Immunogenetics (IMGT) database (http://imgt.org) and all TCR gene segments were
designated according to the IMGT nomenclature using MiXCR software (Bolotin et al., 2015). Only TCRs with ten reads per clonal
sequencewere taken forward for analysis to ensure low frequency or ambiguous sequence datawas not included. Clonal expansions
were not utilized to calculate gene usage frequencies or in motif analysis to ensure that these results were not impacted by any po-
tential PCR bias during cDNA preparation. TCR sequencing data has been deposited online at https://vdjdb.cdr3.net/ (Bagaev et al.,
2020).
Analysis and Visualization of TCR sequencing data in R
Following processing of raw sequencing data, information was processed and presented using R. General packages used: ‘tcR’
(Nazarov et al., 2015), ‘ggseqlogo’ (Wagih, 2017), ‘gridextra’, ‘ggpubr’, ‘ggforce’ and ‘tidyverse’ (Wickham, 2014). VJ chord dia-
grams: plots were created using the ‘circlize’ package (Gu et al., 2014) and modification of code from vdjtools (Shugay et al.,
2015) to fit specific color schemes. TCR entropy: the Shannon entropy function was used from the ‘tcR’ package (Nazarov et al.,
2015). KL distance: Background V-gene usage was kindly provided by Genomics of Adaptive Immunity laboratory (Prof Chudakov
DM) and is based on data fromBritanova et al. for TRB (Britanova et al., 2016) and unpublished data for TRA. The ‘alazakam’ package
(Gupta et al., 2015) was used to quantify charge and hydrophobicity of the middle 6 amino acids across each CDR3 length.
CDR3 Motif Analysis using GLAM2 and MUSCLE
CDR3 sequences were converted to FASTA format, with the starting cysteine and terminal phenylalanine of each sequence removed
for later analysis. Four sequences were less than 8 amino acids in length and were removed from the analysis (these could not be
processed by GLAM2). GLAM2 was run for batches of protein sequences (p) from the command line using the following parameters:
p -a 6 -b 15 -z 10 -r 4 -n 150000. A high iteration rate (-n) of 150000 over 4 runs (-r) was used (increasing -n, as recommended in the
tutorial) with a minimum number of aligned columns (-a) of 6 and a maximum (b) of 15. A minimum of 10 sequences (-z) was required
for anymotif. Following bulk assessment of all sequences specific to each epitope using GLAM2, sequences were subdivided in sub-
groups using MUSCLE and GLAM2 rerun on these subgroups in order to improve the resolution of discovered motifs and find any
motifs that may have been missed by a bulk analysis. As before, the starting cysteine and terminal phenylalanine were removed, and
sequences placed in the AAStringSet format using the ‘Biostrings’ R package. TheR package ‘muscle’ (Edgar, 2004) was run on each
set of CDR3 sequences with cluster set to ‘‘neighborjoining’’ to produce a neighbor joining tree (frommuscle iteration 2) for later anal-
ysis. Trees were read and converted to a distance object (cophenetic.phylo) using the ‘ape’ package (Paradis and Schliep, 2019).
This object was clustered (method = ‘‘complete’’) and cut (h = 4) using base R to 4 subgroups. Each subgroup was processed in
GLAM2 using the same settings, with rooted and unrooted phylogenetic trees visualized using the ‘ape’ package.
OLGA
TheOLGA (Sethna et al., 2019) software was downloaded (https://github.com/statbiophys/OLGA) and run from the command line on
a tab separated file of FASTA formatted sequences of TCRa and TCRb chains using humanTRA and humanTRB models, respec-
tively. For all data shown in Figure S7, probability of generation values were calculated from sequence alone, without V- or J-
gene information being provided to the computation (this data was inspected and can be provided by the authors). This pGen compu-
tation (without V- or J- gene information) was considered, and decided upon as the authors wanted to investigate how likely each
CDR3was to arise within the repertoire, regardless of its parent V- or J-genes, thus eliminating the effect of having higher probabilities
of generation which simply occur in the context of a given V- or J-gene. This was important as several repertoires exhibited strong VJ
usage bias (Figure 4) which could exert this effect and prevent pGen distributions of each repertoire from being comparable.
Crystallography
Purified pHLA proteins (refolded and produced as described above, using an untagged DRA*01 chain with no biotinylation reaction)
were concentrated in crystal buffer, 10 mM TRIS, 10 mM NaCL buffer pH 7.4 (M117-30-SGP: 8.23 mg/mL, M1208-222-QAR: 8.00 mg/
mL). Purified HLA-DR1-PKY and F11 TCR (expressed and refolded as detailed in Holland et al., 2018) were mixed at an equimolar
ratio to give a total protein concentration of 6 mg/ mL in crystal buffer. The short sequence of PB-1410-422-GMF (Figure 1B) could notCell Reports 32, 107885, July 14, 2020 e6
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OPEN ACCESSbe crystallized so a longer sequence was crystallized at a concentration of 4.50 mg/mL (PGMMMGMFNMLSTVLGVSIL) using a
seeding technique with crystal seeds derived from HLA-DR1-QAR (plates were set manually using a hanging drop method). Crystal
trays were set up using the TOPS screen (Bulek et al., 2012) with sitting drop vapor diffusion plates. Crystallization conditions are
detailed in Table S5. Each TOPS screen buffer condition was dispensed into corresponding wells of an ARI INTELLI-PLATE 96-2
low volume reservoir plate (Art Robbins Instruments, LLC) using an Art-Robbins Gryphon robot (Art Robbins Instruments, LLC.).
From the screen, 60 mL was dispensed into a mother liquor well, and two dispenses of 200 nL into separate sitting drop wells.
200 nL of protein sample was dispensed into the topwell containing 200 nL of a TOPS screen buffer. Plates were immediately imaged
using a Formulatrix Rock Imager 2 (Formulatrix, Inc.) and incubated at 18C, with further images taken at daily intervals to monitor
crystal growth.
X-Ray Crystallographic Sample Preparation and Data Collection
Crystals were collected using 20 mm or 40 mm mounted loops (Molecular Dimensions), immediately snap frozen in liquid nitrogen.
Crystals were subject to X-ray diffraction and data collection at Diamond light source (Dicot, England) (1000 diffraction images taken
at 200 rotation and 0.2 s exposure time). Datasets were processed by the DLS auto-processing servers in implementing either xia2
(3dii or 3d operations) or DIALS, full details Table S5). Processed datasets were analyzed using the program suite CCP4i2 (Collab-
orative Computational Project, 1994). ‘Matthews’ was used to obtain the number of molecules in the asymmetric unit and structures
were solved with ‘Phaser’ using an HLA-DR1 model (1DLH) or ternary complex (1FYT) for molecular replacement (McCoy et al.,
2007). Coordinates and density were refined using an iterative cycle of visualization and modeling using Coot software (Emsley
and Cowtan, 2004) and refinement using REFMAC5 (Murshudov et al., 2011) until convergence of refinement statistics. The GMF
structure file required a change of index to the P 32 2 1 space group following unsuccessful cycles of refinement in the DIALS as-
signed P 31 2 1 space group. Final coordinates were visualized using PyMOL graphics software (Delano, 2002) and contact tables
generated using STACEI (https://github.com/WhalleyT/STACEI) to define the interaction distances, types and partners. Electrostatic
analysis was carried out using the PyMol 2.0 plug-in APBS (Baker et al., 2001).
QUANTIFICATION AND STATISTICAL ANALYSIS
IFN-g ELISpot assays
All tests were carried out in duplicate with a control unstimulated well. The criteria for a positive response was at least double back-
ground (value of SFC in the control well) and mean of two duplicates greater than 20 SFC. For pool screens n = 2 HLA-DR1+ donors
for initial epitope mapping. Assessment of individual peptides n = 4 HLA-DR1+ donors.
Flow Cytometry
HLA-DR1+ donor (n = 5) CD3+/Live/CD4+/Dextramer+ T cell populations were quantified by gating was using two controls, an irrel-
evant HLA-Class-II multimer and the fluorescence minus one stain in which the PE fluorochrome was not present. Gates for the test
population were set based on background staining from the irrelevant HLA-multimer for each donor. All boxplots show median and
IQR, standard output from ggplot2.
TCR sequencing
Calculation of percentage frequencies of V- and J- genes for each epitope specific sample was calculated (clonal frequencies were
not used, just the count for each gene within detected unique clonotypes). To calculate normalized percentage frequency across all
donors, values were summed and normalized to the number of donors (3-5 depending on epitope). Enriched V or J genes were
labeled on the circos plots if the mean frequency exceeded 5%. Shannon entropy of each sample was calculated using the function
from the ‘tcR’ R package (genes numbers were tabulated for each sample and passed to this function). Kullback–Leibler (KL) dis-
tance (divergence) was calculated against background frequencies of the naive repertoire [provided by the Genomics of Adaptive
Immunity laboratory (Prof Chudakov DM) and is based on data from Britanova et al. (2016) for TRB and unpublished data for TRA
data, code is given at https://github.com/ALGW71/ConservedEpitopesIAV].e7 Cell Reports 32, 107885, July 14, 2020
